Tianjin Development(00882.HK): Lisheng Pharmaceutical Announces Interim Results, Net Profit Expected to Grow 126.72% to 418 Million Yuan by 2025

NightAirdropper · 2026-03-10T08:11:11+00:00

Gelonghui March 10th | Tianjin Development(00882.HK) issued an announcement, and Lisheng Pharmaceutical(002393.SZ) released the 2025 annual performance brief. In 2025, the company achieved a total operating revenue of 1.393 billion RMB(, an increase of 4.23% compared to the same period last year), and the net profit attributable to shareholders of Lisheng Pharmaceutical was 418 million RMB, a year-on-year increase of 126.72%.

NightAirdropper

2026-03-10 08:11:11

Gelonghui March 10 — Tianjin Development (00882.HK) issued an announcement, and Lisheng Pharmaceutical (002393.SZ) released a performance forecast for 2025. In 2025, the company achieved a total revenue of 1.393 billion yuan (RMB), an increase of 4.23% compared to the same period last year; net profit attributable to shareholders of Lisheng Pharmaceutical was 418 million yuan, a year-on-year increase of 126.72%.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.